Survival from rare cancer in adults: a population-based study

Gatta, Gemma; Ciccolallo, Laura; Kunkler, Ian; Capocaccia, Riccardo; Berrino, Franco; Coleman, Michel P; Angelis, Roberta De; Faivre, Jean; Lutz, Jean Michel; Martı́nez, Carmen; Möller, Torgil; Sankila, Risto

doi:10.1016/s1470-2045(05)70471-x

Cited by 126 publications

(111 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of vague clinical presentation sometimes and low awareness among physicians, data in the literature on the real incidence of NETs are probably underestimates. Data comparisons in relation to the site of tumour origin are difficult to obtain because of the overall rarity of these neoplasms and their incomplete recognition and documentation in various national cancer registries (Gatta et al 2006) and because of their variable and sometimes imprecise classification (Kloppel et al 2009, Klimstra et al 2010.…”

Section: Discussionmentioning

confidence: 99%

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

Niederle

Hackl²,

Kaserer³

et al. 2010

Endocrine-Related Cancer

399

292

View full text Add to dashboard Cite

As incidence data on gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have so far only been retrospectively obtained and based on inhomogeneous material, we conducted a prospective study in Austria collecting all newly diagnosed GEP-NETs during 1 year. Using the current WHO classification, the tumor, nodes, metastases (TNM) staging and Ki67 grading and the standard diagnostic procedure proposed by the European Neuroendocrine Tumor Society (ENETS), GEP-NETs from 285 patients (male: 148; female: 137) were recorded. The annual incidence rates were 2.51 per 100 000 inhabitants for men, 2.36 per 100 000 for women. The stomach (23%) was the main site, followed by appendix (21%), small intestine (15%) and rectum (14%). Patients with appendiceal tumours were significantly younger than patients with tumours in any other site. About 46.0% were classified as benign, 15.4% as uncertain, 31.9% as well differentiated malignant and 6.7% as poorly differentiated malignant. Patients with benign or uncertain tumours were significantly younger than patients with malignant tumours. Among the malignant tumours of the digestive tract, 1.49% arose from neuroendocrine cells. For malignant gastrointestinal NETs, the incidence was 0.80 per 100 000: 40.9% were ENETS stage I, 23.8% stage II, 11.6% stage III and 23.8% stage IV. The majority (59.7%) were grade 1, 31.2% grade 2 and 9.1% grade 3. NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated. G3 tumours are very rare.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

Niederle

Hackl²,

Kaserer³

et al. 2010

Endocrine-Related Cancer

399

292

View full text Add to dashboard Cite

show abstract

“…Recent studies evidenced that epigenetic alterations may play a role in the development and progression of SGT (32)(33)(34)(35). However, a relatively limited variety of SGT histotypes and genes analyzed for epigenetic regulation has been examined (36).…”

Section: Discussionmentioning

confidence: 99%

The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours

Staibano

Mascolo²,

Rocco³

et al. 2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Salivary gland tumours (SGT) constitute a diagnostically challenging group of neoplasms with frequently unpredictable clinical outcome. The proliferation rate facilitates the identification of aggressive SGT. The Chromatin Assembly Factor-1 (CAF-1) is a major epigenetic regulator of nuclear chromatin organization during DNA replication. It plays a critical function in human tumourigenesis and has been proposed as a new proliferation and prognostic marker for some malignancies. This study focused on the role of CAF-1/p60 protein as a marker of clinical value for SGT. The expression of CAF-1/p60 was evaluated by immunohistochemistry on a retrospective series of 362 surgically excised benign and malignant SGT with different histogenesis and, when available, on fine-needle pre-surgical cytological biopsies. The resulting data were compared with traditional prognostic parameters, including the expression of the routine proliferation marker ki67/MIB1. CAF-1/p60 was detectable in all SGT, with highest degree of expression in metastasizing malignant tumours. Moreover, the cases of benign tumours which progressed to carcinoma during the follow-up, showed significantly higher CAF-1/p60 expression than nonprogressing benign SGT, both on histological sections and cytological smears of the primary tumour. Cox's multiple regression analysis selected CAF-1/p60 expression as the best independent predictor of cancer development for benign SGT (p<0.0001), and the best independent predictor of metastasis onset for malignant tumours (p<0.0004). Overexpression of CAF-1/p60, on histological and/or cytological samples, characterizes malignant SGT with aggressive behaviour, irrespective of their specific histotype, and allows the early diagnosis of progression toward malignancy of morphologically benign tumours.

show abstract

“…This leads to uncertainty about the applicability of the results of studies to elderly patients in terms of both the efficacy and toxicity of treatments. In MPM, older age has been generally considered a negative prognostic factor (Herndon et al, 1998;Gatta et al, 2006). Apart from age-related biological differences, this may also have been influenced by a nihilistic attitude to treatment of this disease (Treasure and Sedrakyan, 2004).…”

Section: Discussionmentioning

confidence: 99%

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

et al. 2008

View full text Add to dashboard Cite

The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m À2 and carboplatin AUC 5 mg ml À1 min À1 intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those X70 years old. A total of 178 patients with an ECOG performance status of p2 were included. Median age was 65 years (range 38 -79), with 48 patients X70 years (27%). Grade 3 -4 haematological toxicity was slightly worse in X70 vs o70-year-old patients, with neutropenia observed in 25.0 vs 13.8% (P ¼ 0.11), anaemia in 20.8 vs 6.9% (P ¼ 0.01) and thrombocytopenia in 14.6 vs 8.5% (P ¼ 0.26). Non-haematological toxicity was mild and similar in the two groups. No significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P ¼ 0.47), time to progression (7.2 vs 7.5 months, P ¼ 0.42) and survival (10.7 vs 13.9 months, P ¼ 0.12). Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.

show abstract

Survival from rare cancer in adults: a population-based study

Cited by 126 publications

References 21 publications

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters

The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

Contact Info

Product

Resources

About